In a report released yesterday, Maury Raycroft from Jefferies maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $325.00.
Maury Raycroft has given his Buy rating due to a combination of factors surrounding Alnylam Pharma’s strategic positioning and market opportunities. The upcoming PDUFA decision for Amvuttra’s label expansion in ATTR-CM presents a significant market opportunity, with global sales projected to reach $12 billion by 2028. The anticipated strong label approval, supported by the HELIOS-B trial results, suggests a potential for faster-than-expected market uptake, particularly among second-line TAF progressors and switches.
Additionally, Alnylam’s existing commercial presence in the PN market provides a strategic advantage for the launch of Amvuttra in the CM space. The company’s pricing strategy, which may align with current PN pricing, and the expected lack of step edit requirements further bolster the positive outlook. Alnylam’s established relationships with healthcare providers and systems, along with favorable payer dynamics, position the company well to capitalize on this growth opportunity, supporting Raycroft’s Buy rating.
In another report released on March 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $500.00 price target.
ALNY’s price has also changed slightly for the past six months – from $274.460 to $253.110, which is a -7.78% drop .
Questions or Comments about the article? Write to editor@tipranks.com